VasGene Therapeutics, Inc.; Veglin trial shows potential in fighting angiogenesis and tumor progress...
VasGene Therapeutics, Inc.; Veglin trial shows potential in fighting angiogenesis and tumor progression
About this item
Full title
VasGene Therapeutics, Inc.; Veglin trial shows potential in fighting angiogenesis and tumor progression
Publisher
Atlanta: NewsRx
Journal title
Biotech Week, 2004, p.745
Language
English
Formats
Publication information
Publisher
Atlanta: NewsRx
Subjects
More information
Scope and Contents
Contents
In 2003, a phase I trial of Veglin was initiated for patients with any malignancy that failed to respond to previous treatment. The primary objective of this study was to determine the maximum tolerated dose and toxicity profile of Veglin among relapsed and refractory patients with a variety of tumor types.
Alternative Titles
Full title
VasGene Therapeutics, Inc.; Veglin trial shows potential in fighting angiogenesis and tumor progression
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_205610305
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_205610305
Other Identifiers
ISSN
1535-2757
E-ISSN
1537-1395
How to access this item
Log in as a Library member
